AI Terminal
INTELLIGENT ULTRASOUND GROUP PLC
Earnings Release • Jul 24, 2023
7714_rns_2023-07-24_e78c3615-dcd6-49ad-89b9-edd439a9d5fe.html
Earnings Release
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 8680G
Intelligent Ultrasound Group PLC
24 July 2023
24 July 2023
The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.
Intelligent Ultrasound Group plc
(the "Group")
Trading update
Intelligent Ultrasound Group plc reports positive trading period in H1
Intelligent Ultrasound Group plc (AIM: IUG) ("Intelligent Ultrasound" or "the Group"), the 'classroom to clinic' ultrasound company specialising in artificial intelligence (AI) software and simulation, today provides a trading update for the six months to 30 June 2023.
Financial highlights:
· The Group expects to report that revenue for the period to 30 June 2023 has grown by 3% to £6.1m (H1 2022: £5.9m)
o H1 2022 revenue figures included £1.4m of one-off orders from the NHS in the UK, so on an adjusted like-for-like basis, revenue in H1 2023 is expected to have increased by 35% (H1 2022 adjusted: £4.5m)
· The Group's clinical AI products continue to gain traction and revenues are expected to have more than doubled to £0.7m (H1 2022: £0.3m)
· Cash at bank on 30 June 2023 was £3.4m (31 December 2022: £7.2m), impacted by working capital seasonality in H1
· Cash utilisation in H2 is expected to be materially lower and the Group remains on target to reach profitability with its current cash
The company will publish its half-year results in August.
For further information, please contact:
| Intelligent Ultrasound Group plc | www.intelligentultrasound.com |
| Stuart Gall, CEO | Tel: +44 (0)29 2075 6534 |
| Helen Jones, CFO | |
| Cenkos Securities - Nominated Advisor and Broker | |
| Giles Balleny/Max Gould (Corporate Finance) | Tel: +44 (0)20 7397 8900 |
| Michael Johnson/Julian Morse (Sales) | |
| TB Cardew - PR Advisors Ed Orlebar |
[email protected] Tel: +44 (0)7738 724630 |
| Allison Connolly | Tel: +44 (0)7587 453955 |
| Emma Pascoe-Watson | Tel: +44 (0)7774 620415 |
| Hero Kurzeja | Tel: +44 (0)7827 130430 |
About Intelligent Ultrasound Group
Intelligent Ultrasound (AIM: IUG) is one of the world's leading 'classroom to clinic' ultrasound companies, specialising in real-time hi-fidelity virtual reality simulation for the ultrasound training market ('classroom') and artificial intelligence-based clinical image analysis software tools for the diagnostic medical ultrasound market ('clinic'). Based in Cardiff in the UK and Atlanta in the US, the Group has two revenue streams:
Simulation
Real-time hi-fidelity ultrasound education and training through simulation. Our main products are the ScanTrainer obstetrics and gynaecology training simulator, the HeartWorks echocardiography training simulator, the BodyWorks Eve Point of Care and Emergency Medicine training simulator with Covid-19 module and the new BabyWorks Neonate and Paediatric training simulator. To date over 1,500 simulators have been sold to over 750 medical institutions around the world.
Clinical AI software
Deep learning-based algorithms to make ultrasound machines smarter and more accessible using our proprietary ScanNav ultrasound image analysis technology. Current products on the market utilising this technology are GE Healthcare's SonoLyst software that is incorporated in their Voluson Expert 22 and SWIFT ultrasound machines; ScanNav Anatomy PNB that simplifies ultrasound-guided needling by providing the user with real-time AI-based anatomy highlighting for a range of medical procedures; and NeedleTrainer that teaches real-time ultrasound-guided needling and incorporates ScanNav Anatomy PNB.
NOTE: ScanNav Anatomy PNB is CE approved and cleared for sale in the US by the FDA, but is not available for sale in any other territory requiring government approval for this type of product.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
TSTFLFEDDFILFIV